PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.
Androgen-deprivation therapy (ADT) for more than 1 year is associated with a 2.5 times higher odds of fracture in prostate cancer patients.
Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.
But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.
Starting docetaxel with androgen deprivation therapy prolonged median overall survival by more than 13 months versus ADT alone.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.
Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.
It is beneficial in terms of muscle strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue.
Liberal use of androgen deprivation therapy likely gave prostate cancer patients a fracture risk comparable to that of the cancer itself.
Acute kidney injury was most likely to develop in men receiving combined androgen blockade.
Study reveals lower risk of developing castrate-resistant prostate cancer.
Integrated prostate cancer centers have greater use of intensity modulated radiation therapy.
Testosterone takes a long time to recover, so PSA levels in prostate cancer patients may remain low.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
A large, international trial has found intermittent ADT is not equivalent to continuous ADT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
Nearly 189,000 men with nonmetastatic disease are receiving continuous ADT for six months or more, researchers estimate.
Men with prostate cancer receiving ADT who experience a fracture may have a 1.38-fold higher mortality risk.
Risk is unaffected by orchiectomy, large Danish study finds.
Elevated risk of gallbladder problems found with use of GnRH agonists.
Researchers concluded that exercise be considered as an adjunctive therapy in men undergoing androgen suppression.
Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.
The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression.
New data indicate a sustained and substantial overall and disease-specific survival benefit associated with androgen deprivation therapy (ADT) plus radiation therapy among patients with locally advanced prostate cancer.
Have you ever placed a prostate cancer patient on intermittent rather than continuous androgen deprivation therapy?June 05, 2012
Recent studies have looked at the use of intermittent ADT as way to spare prostate cancer (PCa) patients some of the adverse effects associated with continuous ADT.
Androgen deprivation therapy (ADT) prior to salvage cryotherapy does not improve biochemical-free survival (BFS) at five years, according to data presented at the American Urological Association 2012 annual meeting.
Adding radiotherapy to androgen deprivation therapy (ADT) improves outcomes in patients with locally advanced prostate cancer (PCa) and can be considered a standard treatment option.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)